For primary hyperlipidemia. ANDA 206047, held by Zydus Pharms. Pitavastatin Calcium.
As of Nov 16, 2026, ANDA 206047 (Pitavastatin Calcium), held by Zydus Pharms, was first approved by FDA on Feb 22, 2023, with 1 approved supplement and 0 published complete response letters.
Pitavastatin is indicated as an adjunct to diet to reduce low-density lipoprotein cholesterol (LDL-C) in: Adults with primary hyperlipidemia. Adults and pediatric patients aged 8 years and older with heterozygous familial hypercholesterolemia (HeFH).
| Date | Submission | Status | Documents |
|---|---|---|---|
| Feb 22, 2023 | Original application | Approved | None posted |
| Pitavastatin CalciumEQ 1MG BASE · tablet;oral | Pitavastatin Calcium | Rx |
| Pitavastatin CalciumEQ 2MG BASE · tablet;oral | Pitavastatin Calcium | Rx |
| Pitavastatin CalciumEQ 4MG BASE · tablet;oral | Pitavastatin Calcium | Rx |
| Jun 11, 2024 | Supplement 2Labeling · Standard review | Approved | None posted |
| Feb 22, 2023 | Original application | Approved | None posted |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. Drugs@FDA and FDA complete response letters